Not available
Quote | Regulus Therapeutics Inc. (NASDAQ:RGLS)
Last: | $2.22 |
---|---|
Change Percent: | -1.33% |
Open: | $2.29 |
Close: | $2.22 |
High: | $2.29 |
Low: | $2.22 |
Volume: | 91,807 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Regulus Therapeutics Inc. (NASDAQ:RGLS)
2024-04-10 12:51:42 ET Summary Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction of cysts. Additional results from cohort 3 of...
2024-04-09 17:06:43 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics Read the full article on Seeking Alpha For...
Message Board Posts | Regulus Therapeutics Inc. (NASDAQ:RGLS)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $RGLS 35% v1,4M c1.22 f16,840M H1.3499 ML.76 RL.88 | znewcar1 | investorshangout | 04/13/2023 9:17:51 PM |
I took a much larger position after $RGLS | jimmy667 | investorshub | 09/15/2022 2:28:08 AM |
Hi Jimmy, yes I agree. Investors starting to | subslover | investorshub | 09/14/2022 8:26:12 AM |
very strong clinical science | jimmy667 | investorshub | 09/14/2022 5:08:59 AM |
Very strong today! | subslover | investorshub | 09/12/2022 1:47:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Domin...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial re...